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INTRODUCTION
F 1 F o ATPase is a multi-subunit transmembrane enzyme that was initially localized in the inner side of the mitochondrial membrane. Interestingly, it is now recognized that the F 1 complex, composed by α,β,γ,δ,ε subunits, that contains the catalytic site for ATP synthesis or hydrolysis is expressed at the plasma membrane of different cell types and represents a cell surface receptor for apparently unrelated ligands (1) . In particular, F 1 -ATPase at the cell surface of human umbilical vascular endothelial cells (HUVEC) or hepatocarcinoma and lung cancer cells has been described as a receptor for angiostatin, a proteolytic fragment of plasminogen. In these cells, angiostatin binds to the cell surface F 1 -ATPase, inhibits ATP production, leading to cell death, anti-tumorigenic or anti-angiogenic effects (2) (3) (4) (5) . Endothelial cell surface F 1 -ATPase also serves as a receptor for apolipoprotein-AI (apo-AI). This lipoprotein stimulates cell surface F 1 -ATPase activity, leading to ADP production and an increase in proliferation of HUVEC (6) . In addition, ApoA-I interacts with the F 1 -ATPase at the cell surface of hepatocytes playing a role in HDL endocytosis (7) . In the present study, using immunofluorescence approaches and confocal microscopy, we demonstrate for the first time the presence of the F 1 -ATPase at the cell surface of colonic epithelial cells. More interestingly, using Surface Plasmon Resonance (SPR) technology coupled to mass spectrometry we have identified a new ligand of the F 1 -ATPase, a peptide hormone product of the gastrin gene, the glycine-extended form of gastrin (G-gly). G-gly is the first gastrin precursor for which growth factor properties were demonstrated (8) . Subsequently, numerous publications have reported the proliferative effects of G-gly on normal and cancerous gastrointestinal cells in vitro and in vivo (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In addition, G-gly induces tubule formation by human vascular endothelial cells in vitro in a similar manner to VEGF, suggesting a potential proangiogenic role for this peptide (19) . So far, the membrane receptor for G-gly has not been identified. This gastrin precursor does not bind the receptor specific for the mature form of the hormone and several publications show that G-gly proliferative effects are independent from the gastrin receptor (8, 11, 20) . However, we and others have previously demonstrated, the presence of high affinity G-gly binding sites on gastrointestinal cells suggesting the existence of G-gly receptors at the cell surface (8, 11) . Here, by molecular modeling and validation of this model with mutagenesis and biological analysis, we have characterized the molecular interaction between G-gly and the F 1 -ATPase. We have also identified the function of the F 1 -ATPase activated by G-gly at the cell surface of colonic epithelial cells.
EXPERIMENTAL PROCEDURES
Cell culture: HCT116, HT29 and CACO-2 cells were obtained from the American Type Culture Collection (LGC Standards, France), Human Umbilical Vein Endothelial Cells (HUVEC) from Millipore (Tebu Bio, France), YAMC cells was kindly provided by Robert H. Whitehead (Vanderbilt University Medical Center, Nashville, USA) and grown as previously described (4, 13, 45) . Purified membranes: Cells were scraped and lysed in a phosphate buffer (pH 7.4) through freezing/thawing cycles. After centrifugation 15min at 1000 rpm, the pellet was homogenized in 0.3M sucrose then centrifuged 2h15 at 27000 rpm in 10 ml of 1.63M sucrose (final sucrose molarity 1.56M). The purified plasma membrane were collected at the interface of the sucrose gradient and diluted in 1ml of a Tris buffer (20 mM) pH 7.4 supplemented by soybean trypsin inhibitor (0.1mg/ml). The proteins concentration was determined by BCA assay kit (Pierce). F 1 -ATPase and IF1 preparation: F 1 -ATPase was purified from bovine heart mitochondria as previously described (21) and kindly provided by J. Walker (MRC Mitochondrial Biology Unit, Cambridge, UK). The plasmid encoding bovine mutated form IF1 (IF1-H49K, histidine 49 switched to lysine) was kindly provided by J. Walker and protein expression and purification were carried out as previously described (22) . Surface Plasmon Resonance assays: Studies based on SPR technology were performed on a BIAcore 3000 optical biosensor instrument (BIAcore AB, Uppsala, Sweden). Immobilization of biotinylated peptides was performed on a streptavidin-coated sensorchip in HBS-EP buffer (10mM Hepes pH 7.4, 150mM NaCl, 3mM EDTA, 0.005% surfactant P20). All immobilization steps were performed at a final peptide concentration of 50 ng/ml (flow rate 10 µl/min). Injections were stopped when a level of 350 RU was obtained. A channel was left empty and was used as a reference surface for non-specific binding measurements. The analyte was injected over the immobilized peptides for 4 minutes (flow rate 30 µl/min) in a K-Inject mode. Kinetics constants (Ka and Kd) were calculated using BIAevaluation 4.0.1 software. Kd was calculated as the ratio of Kd/Ka. For recovery strategy, biotinylated G-Gly peptide was immobilized on 3 channels of a SA sensorchip at a level of 900 RU per channel with an empty channel as reference surface. Solubilized membrane proteins were injected for 6 min (20ul/min flow rate). Four cycles of recovery with a 50mM-TEA/0,5M-Urea solution were performed to obtain 27 000 RU of recovered proteins corresponding to 27ng of proteins. Recovered proteins were subjected to mass spectrometry analysis for identification (NanoLC/ESI QStar MS/MS, IPBS Toulouse Genopole). Molecular Modelling: The sequence of G-gly was aligned to several species of IF1 using the ClustalX program (40) and adapted for the figure using the GeneDoc program. The amino acid sequence files with the code P01096, Q9UII2, Q03344, O35143, P01097 and P09940 were downloaded from the Expasy server. The secondary structure and threedimensional model of G-gly are predicted using the PEP-FOLD server (26) . The model of G-gly was rigidly docked to the crystal structure of F1-ATPase (PDB code: 2V7Q) using the Glide module of Schrodinger software (Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009). The box was centered based on the position of IF1 in the crystal structure of 2V7Q, and the size of the docking box, 30x30x30 was used. The SP scoring function of Glide was chosen and 40 poses were generated. The selected docking pose was chosen for the optimization of the peptide-enzyme interactions using 500ps molecular dynamics simulations in implicit solvent, using the Schrodinger software. The picture was prepared in the Schrodinger software (Maestro, version 9.1, Schrödinger, LLC, New York, NY, 2010.). Immunofluorescence and confocal microscopy: CACO-2 cells were plated on TranswellClearTM filters (Corning, Costar) at high density in order to obtain confluence in 5-8 days. 8 to 10 days post-confluent CACO-2 cells (to obtain well polarized cells), were fixed and permeabilized using standard methods. For all other lines, cells were grown in Lab-Tek chambered coverglass and Immuno-stainings were performed on intact cells, non-fixed, non-permeabilized using standard methods. Antibodies used: anti-β-ATPase (Molecular Probes), anti-EGFR and anti E-cadherin (Cell Signaling), DPP-IV (R&D Systems). When mentioned, cells were incubated with Mitotracker Red (Molecular Probes) 10 nM for 15 Min at 37°C. After washes in PBS, the cells are visualized by confocal microscopy. For immunostaining on the formaldehyde-fixed, paraffin embedded tissues (colonic tissue of mouse), heat induced epitope retrieval was performed in 10 mM citrate buffer and primary antibodies were applied overnight (anti-β-ATPase from Molecular Probes and anti E-Cadherin from Cell Signaling). The detection was done using Alexa Fluor 488 goat anti-mouse antibody and Alexa Fluor 647 donkey anti-rabbit(Molecular Probes). Control slides, where the primary antibody was replaced by non-immune IgG, were checked for non-specific reactivity. Slides were analyzed by confocal microscopy (magnificence X40). ADP generation assay: HUVEC in 6-well plates were washed and incubated for 1h at 37°C in serum free medium, then [α-32P]ATP (0.5 µCi/well) (Perkin-Elmer) was added for 10 min at 37°C with or without treatments. Nucleotides were then separated by HPLC and quantified as previously described (12 
RESULTS

Identification of the plasma membrane F 1 F oATPase as a potential binding protein for Ggly
We previously reported G-gly proliferative effects on the human colon cancer cells HCT116 (9) . Here, we have purified plasma membranes from the HCTT16 cells. Solubilized membrane proteins were then tested for their interaction with G-gly by Surface Plasmon Resonance (SPR, BIAcore 3000) using biotinylated G-gly immobilized on the BIAcore sensor chip. Biotin alone was coated as a control. As shown by the sensogram (figure 1), we observed a remarkable increase in the interaction with biotinylated G-gly compare to biotin alone indicating the presence of potential G-gly binding proteins in the purified plasma membranes of HCT116 cells. Following a recovery procedure, membrane proteins bound to G-gly were analyzed by mass spectrometry (nanoLC/ESI QStar MS/MS) and we identified, using the Mascot search engine, different subunits that compose the F 1 complex of the F 1 F o -ATPase (table 1) .
Because several publications have demonstrated that binding of two ferric ions to G-gly is essential for the biological activity of the peptide (25, 26) , we analyzed the interaction between the solubilized membrane proteins and G-gly employing SPR in the presence or absence of desferrioxamine (DFO), a ferric ions chelator, which is known to inhibit the proliferative effect of G-gly in the HCT116 cells (9) . As expected, the sensogram in figure  2A shows a decrease (42%) of the G-gly binding to the solubilized proteins in the presence of DFO, suggesting a role of ferric ions in the interaction of G-gly to its potential binding proteins. Eluted proteins were resolved by SDS-PAGE and silver stained (figure 2B). Interestingly, staining of the bands around 50 kDa was decreased by the pretreatment with DFO indicating a decrease in the interaction of G-gly with these proteins. We specifically cut the corresponding bands from the gel and identified the proteins by mass spectrometry. The α  and β-subunits of the F 1 -ATPase were clearly identified with a good score (table 2) .
Direct interaction of G-gly with F 1 -ATPase
We used the SPR technology to verify the direct interaction between purified F 1 -ATPase ( figure 3A ) and G-gly. The sensograms in figure 3B show a direct interaction between G-gly coated on the BIAcore sensor chip and the purified F 1 -ATPase used as an analyte. Binding of F 1 -ATPase to the immobilized G-gly was dosedependent (3-50 nM) allowing us to determine the affinity between this multi-subunit complex and the gastrin precursor, G-gly (KD ~1.7 nM).
Computational study of the G-gly interactions with the F 1 -ATPase
We examined the molecular basis of interactions between G-gly and F 1 -ATPase by molecular modeling. The prediction of the secondary and three-dimensional structures of G-gly using the peptide structure prediction PEP-FOLD server shows that G-gly is a likely α-helix. We noted that G-gly has an EE/DxY motif also found in IF1, an α-helical natural inhibitor of F 1 -ATPase. Figure 4A shows the sequence alignment of IF1 from different species and human G-gly, in which the EE/DxY motif can be identified. Because the sequence fragment of IF1 corresponding to Ggly is a helix, it additionally supports the helical nature of G-gly predicted by the webserver. The crystal structure of IF1 in the complex with F 1 -ATPase in which IF1 is bound to α and β subunits, and makes few contacts with the δ-subunit is available (PDB code: 2V7Q). Given that our experimental studies predicted the direct interactions of Ggly with mainly α and β subunits and possibly the δ-subunit, we docked the α-helical structure of G-gly to F 1 -ATPase, specifying the docking box around the position of IF1 in the crystal structure. Among generated docking poses of G-gly, we selected for detailed examinations, the pose in which the residues of the EE/DxY motif form contacts similar to IF1, thus preserving the molecular recognition pattern, which has been recently shown to be an essential component to the binding energy that holds IF1 and F 1 -ATPase together (27) . The position of G-gly and its interactions with F 1 -ATPase are shown in Figure 4 (B, C, D). We propose that G-gly is bounded to the β-subunit through several interactions: (i) the salt bridges involving E9 and E10 of G-gly and R408 of the β-subunit (ii) a hydrogen bond between E9 and Y381 (iii) hydrophobic and van der Waals interactions of L5, Y12 and F17 with M393, K401 I388, P453 and Q455 of the β-subunit (iiii) hydrogen bonds between G18 and H477 and E7 and A401. G-gly also interacts with the α-subunit through hydrophobic and van der Waals interactions of W4, A11 and W14 with F403, V400, L417 and Q396 of the α-subunit. There is no direct contact of G-gly with the δ-subunit in this binding mode, although some docking solutions provided few contacts with the δ-subunit. The salt bridge between E9 and R408 corresponds to similar interactions between E30 of IF1 and R408. This interactions have been recently shown by mutagenesis to play an important role in bovine and yeast IF1 binding to F 1 -ATPase (27) . in particular, mutation of bovine E30 (yeast E25) to alanine strongly decreases the binding (27) .
Loss of interaction between the F 1 -ATPase and G-gly with a mutation in the EE/DxY domain
On the basis of our SPR studies and molecular modeling, we propose that binding of G-gly into F 1 -ATPase may occur in a similar fashion to IF1. To confirm this hypothesis, we mutated the E9 residue of Ggly to alanine and analyzed by SPR the interaction between this mutated form of the peptide and the F 1 -ATPase. As shown by the sensograms in figure 5 , the binding of G-gly coated on the BIAcore sensor chip to the purified F 1 -ATPase used as an analyte is abolished when E9 of G-gly is mutated to alanine. The natural receptor of the mature amidated form of gastrin is the CCK2 receptor, a G protein-coupled receptor, mainly localized in the stomach. However, we verified the potential interaction between gastrin-amide (G-NH2) and the F 1 -ATPase. As expected, we did not observe any interaction, by SPR, between the F 1 -ATPase and G-NH2 (figure 5).
Localization of F 1 -ATPase at the cell surface of normal and tumor colonic cells
The expression of F 1 -ATPase at the plasma membrane of normal and tumor colonic epithelial cells has never been reported. We performed immuno-staining with an antibody against the β-subunit of F 1 -ATPase on nonfixed non-permeabilized living cells. In these conditions, the βF 1 antibody interacts only with proteins localized at the cell surface. Analysis by confocal microscopy shows a βF 1 staining on the cell surface of 2 colon cancer cell lines, HCT116 and HT29, in which we previously reported a biological effect of G-gly (figure 6 a,d) (9, 28) . These results suggest that the orientation of the F1-ATPase in the membrane is such that the F1 component is extracellular and available to the antibody. These patch-like structures did not colocalize with Mitotraker Red, a specific marker of mitochondria ( figure  6 g, h) . Using an antibody directed against a membrane receptor (EGFR), as a control, we observed a staining at the cell surface similar to that of plasma membrane βF 1 (figure 6 b, e). In contrast, when cells were permeabilized (figure 6 i) the F 1 -ATPase staining was intracellular, localized to mitochondria as expected.
Since the proliferative effects of G-gly have also been observed on normal colonic epithelial cells (11, (29) (30) (31) , we analyzed the expression of F 1 -ATPase at the cell surface of a nontransformed colon cell line, YAMC, on which a previous report has demonstrated the presence of specific binding sites for G-gly and a proliferative effect of the peptide (11) .
Similarly to what we observed for colon cancer cell lines, confocal microscopy analysis on non-fixed, non-permeabilized living cells show βF 1 staining on the cell surface of YAMC that does not colocalize with Mitotraker Red ( figure 6 j) . In addition, G-gly proliferative effects have been previously reported on normal epithelial cells from the colonic mucosa of mice (22) . Here we confirmed on mouse colonic tissue sections the plasma membrane localization of the F 1 -ATPase on normal colonic epithelial cells. Indeed, by confocal microscopy using antibodies that detect specifically, βF 1 or E-Cadherin, known to be localized on the basolateral membrane, we observed a co-staining of the two proteins at the membrane of colonic epithelial cells ( figure 7A ). To confirm the location of the F 1 -ATPase on the basolateral membranes of polarized colonic epithelial cells, we used specific markers of respectively the apical or basolateral membranes on a monolayer of polarized CACO-2 cells. Confocal X-Y (top and bottom of the cells) ( figure 7B ) and Z sections ( figure 7C ), show the absence of apical labeling with the βF 1 antibody whereas the staining for DPP-IV, a marker of apical membranes is positive. On the contrary, we observed the presence of a basolateral labeling for F1-ATPase as well as for E-cadherin.
Cell surface F 1 -ATPase activity is stimulated by G-gly.
Several works have reported the presence F 1 -ATPase at the cell surface of human umbilical vascular endothelial cells (HUVEC) and demonstrated its role in angiogenesis. In particular, Radojkovic et al. reported that F 1 -ATPase on the surface of endothelial cells serves as a receptor for apolipoprotein-AI (apo-AI). This lipoprotein stimulates cell surface F 1 -ATPase activity, leading to ADP production and an increase in proliferation of HUVEC (6) . A recent work showed that G-gly is capable to increase tubule and node formation by HUVEC (19) . We therefore hypothesize that G-gly might stimulate the cell surface the peptide, as previously described (6) . In the presence of G-gly we observed an increased hydrolytic activity on HUVEC (+ 46% ± 6) (figure 8A) similar to that previously described for apo-AI on the same cells (6) . The ability of IF1 protein to specifically inhibit the hydrolytic activity of F 1 -ATPase is well documented. The efficiency of this natural inhibitor is pH-dependent. We therefore used a mutated form of IF1 (IF1-H49K) known to be active at all pH values. As previously reported in the HUVEC cells, IF1-H49K decreases the basal extracellular ADP production (6) but more interestingly reverses ATP hydrolysis and ADP production in response to G-gly ( figure 8A) . Similar results were obtained on colonic epithelial cancer cells (+ 21.5 ± 2.3) (figure 8B), indicating that the membrane F 1 -ATPase is also functional on this cellular model and leads to ATP hydrolysis. Cell surface ATPase on endothelial cells has been previously shown to regulate the intracellular pH (32). Here we have analyzed whether G-gly induces intracellular acidification on colonic epithelial cell. pHi was measured using the pH-sensitive fluorescent probe carboxy-SNARF-1 and flow cytometry analysis as described in "Methods". Experiments were performed in neutral extracellular pH conditions for which we observed ADP production and cell proliferation in response to G-gly. As shown in figure 8C , pHi is not significantly modified after 10 minutes of G-gly treatment as compared to control (respectively 7.23 ± 0.03 and 7.25 ± 0.05). Similar results were obtained for longer times of stimulation (1h to 48h data not shown). The dimethyl amiloride (DMA), an inhibitor of the Na+/H+ exchanger, was used as an acidifying positive control. As expected we observed at 10 minutes an acidification of the pHi with DMA compared to the control condition (6.84 versus 7.29 pvalue = 0.0001).
Cell surface F 1 -ATPase mediates G-gly proliferative effects on endothelial cells and colon cancer cells.
In order to demonstrate the role of F 1 -ATPase in mediating the growth factor effect of G-gly, we performed proliferative assays on HUVEC and colon cancer cells in the presence of the F 1 -ATPase inhibitor, IF1-H49K. Stimulation of HUVEC (figure 9A) or HCT116 cells (figure 9B) by G-gly induced a significant increase of cell proliferation. These effects were completely abolished when the cells were pretreated with the F 1 -ATPase inhibitor, indicating that the effects of G-gly on cell survival are lost when the F 1 -ATPase is inhibited. To confirm the involvement of cell surface F 1 -ATPase in the growth factor effect of G-gly, proliferative assays were also performed in the presence of an anti-β-F 1 -ATPase blocking antibody which was shown to bind to the cell surface F 1 -ATPase. As shown in figure 9 the blocking antibody could abolish G-gly-induced cell proliferation on endothelial cells ( figure 9A ) and colon cancer cells ( figure 9B ) similarly to what we observed with IF1 on these cellular models. These results confirm that the cell surface F 1 -ATPase plays an important role in mediating growth factor effects of G-gly in both endothelial cells and colon cancer cells. We also used angiostatin another ligand of membrane F 1 -ATPase known to inhibit endothelial cell proliferation. By treating colon cancer cells with a concentration of angiostatin previously used in other studies (6), we confirmed its ability to inhibit cell proliferation. In addition, G-gly proliferative effects were abolished when the colon cancer cells were pretreated with angiostatin ( figure 9B ).
On the basis of SPR studies and molecular modeling, we proposed that binding of G-gly into F 1 -ATPase involves the EE/DxY motif conserved in the G-gly and IF1 sequences. Since mutation of the E9 residue of G-gly into alanine strongly decreases the binding of the peptide to the F 1 -ATPase, we also tested the ability of the mutated G-gly to stimulate cell proliferation. As shown in figure  9C , the proliferative effect observed when colon cancer cells are stimulated with 1 nM of G-gly is totally absent when a similar concentration of the mutated peptide is used (G-gly-E9A). Higher concentrations of G-gly-E9A were also tested in proliferation assays (10 to 1000 nM) but none was efficient to stimulate cell proliferation (data not shown). As expected, the proliferation of HCT116 cells that do not express the CCK2 receptor was not stimulated by gastrin-amide (figure 9C).
DISCUSSION
Although F 1 F o ATPase was initially believed to be strictly expressed in the inner membrane of mitochondria, recent studies have shown that the F1 complex, containing the catalytic site for ATP synthesis or hydrolysis is expressed at the cell surface of endothelial cells, hepatocytes as well as hepatoma and lung cancer cells (1) . This complex has been characterized as a cell surface receptor for different ligands. In the present study, we have identified by mass spectrometry, in the purified plasma membranes from colorectal cancer cells different subunit of the F1 complex (α, β, δ). In addition, using immunofluorescent approaches and confocal microscopy, we confirmed the presence of the F 1 -ATPase at the cell surface of different colon cancer cell lines and in the plasma membrane of normal colonic epithelial cells. F 1 -ATPase, at the cell surface of endothelial cells as well as hepatoma and lung cancer cells, has been described as a receptor for angiostatin that mediates cell death through the inhibition of ATP production (2) (3) (4) (5) . In contrast, apo-AI, another ligand of endothelial cell surface F 1 -ATPase induces cell proliferation and survival by stimulating ADP production (6) . Here, using SPR technology coupled to mass spectrometry, we have identified a gastrointestinal peptide, the glycine -extended form of gastrin, as a new ligand for the F 1 -ATPase that is localized at the cell surface of colonic epithelial cells. Because the gastrin precursor, G-gly does not stimulate gastric acid secretion as does the mature form of the hormone, it was initially considered without biological activity. However we were the first to demonstrate a proliferative effect of this hormonal precursor on tumor cells (8) . Ggly is now clearly established as a growth factor for normal and cancerous gastrointestinal cells particularly from colon origin. However the receptor that mediates the biological activity of this precursor peptide, and might represent a new potential target in gastrointestinal cancers, was unknown. In the present study, we clearly demonstrate, using purified F 1 -ATPase and synthetic G-gly in a SPR approach, the direct interaction between G-gly and the F 1 -ATPase. Interestingly the affinity calculated in these experiments was similar to that previously reported in pharmacological studies for the G-gly high affinity binding sites (8, 11) . In addition by molecular modeling, we identified the motif in the G-gly sequence (EE/DxY) which directly interacts with F 1 -ATPase as well as the aminoacid residues in the β−and α-subunits of the F 1 -ATPase which bind this motif. We confirmed this molecular model by mutation of the EE/DxY motif, in particular, replacement of the E9 residue by an alanine resulted in a strong decrease of G-gly binding to the F 1 -ATPase.
We have also demonstrated the role of the F 1 -ATPase in mediating the growth factor effect of G-gly on both colon cancer cells and HUVEC. Indeed, blocking the F 1 -ATPase with a specific antibody or IF1, a natural inhibitor of the enzyme, abolished G-gly proliferative effects in these cells. The mechanism likely involves ADP production by the membrane F 1 -ATPase. Indeed, in the presence of G-gly the membrane F 1 -ATPase functions as an ATP hydrolase and produces extracellular ADP. These effects are reversed in the presence of IF1, known to inhibit the hydrolytic activity of F 1 -ATPase. In addition, G-gly activity is also abolished by mutation of the EE/DxY motif in the G-gly sequence which directly interacts with the F 1 -ATPase. In contrast G-gly does not regulate pHi in the experimental conditions (neutral pHi) for which we observed ADP production and cell proliferation. Some membrane F 1 -ATPase ligands such as angiostatin have been previously reported to induce cell death by decreasing pHi but only in a low extracellular pH environment (33) .
In vivo, transgenic mice overexpressing circulating G-gly exhibited increased colonic proliferation compared with wild-type controls (31) . Similarly, continuous infusion of G-gly into rats or gastrin-deficient mice also resulted in an increase of colonic proliferation (29) . These results suggest the existence, on colonic epithelium, of a putative receptor or binding protein for G-gly that mediates the proliferative effects of the peptide. Here we have shown that the F 1 -ATPase which directly binds G-gly is present at the plasma membrane of colonic epithelial cells in a mouse model. It is also interesting to notice that in both in vivo models (G-gly transgenic mice or G-gly infusion), treatment of the animals with DFO, a ferric ions chelating agent, reverses the proliferative effects induced by G-gly, suggesting that the biological activity of the peptide is dependent on the presence of ferric ions (34). In vitro studies confirm that G-gly binds two ferric ions necessary to its biological activity (9, 25, 26) . In accordance with these previous data, our results show that the binding of G-gly to its potential receptor is decreased in the presence of ferric ions chelator.
Several studies have suggested a link between F 1 -ATPase and colorectal cancer. Indeed, F 1 -ATPase has been shown to be upregulated in primary colorectal tumors compared to the adjacent normal mucosa (35). In addition, an association between F 1 -ATPase overexpression with poor survival of the patients has been reported in stage III colorectal cancer (36). F 1 -ATPase expression is also upregulated in liver metastasis of colorectal cancer as compared to primary tumor as well as in tumor spheroids of colon carcinoma cells compared to cells grown in monolayer (36, 37). It is therefore interesting to notice that the new ligand of F 1 -ATPase that we have identified in the present study is also overexpressed in these tumor cells. Indeed, the gene coding for gastrin is a target of oncogenic pathways frequently activated in colon cancer such as APC/beta-catenin or Ras pathways (38-41). Therefore, high concentrations of gastrin precursors, including G-gly have been observed in colon tumors and in blood of patients with colorectal cancer (42-45). These data suggest that the cell surface F 1 -ATPase may contribute to a pro-tumoral autocrine loop in colorectal cancer cells. Interestingly, an antitumor strategy using monoclonal antibodies against the β-subunit of F 1 -ATPase has been previously proposed for hepatoma since these antibodies have been shown to reduce growth of these tumors (46). In view of our results, targeting cell surface F 1 -ATPase might be also a new therapeutic approach for colon cancer. In colon cancer, both F 1 -ATPase and its ligand G-gly seems to be overexpressed, an alternative or complementary strategy to F 1 -ATPase blocking could be the use of antibodies against the gastrin precursors.
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